Personalized mRNA vaccine shows promise in reducing melanoma return: Research

Researchers have found that a personalized mRNA vaccine developed by Moderna and Merck significantly reduces the recurrence of melanoma, the most deadly form of skin cancer. After tracking participants over five years following a Phase 2b study, the results indicate promising efficacy. This breakthrough could lead to more effective treatments for melanoma, offering hope for better long-term outcomes for patients battling this aggressive disease.